Recro Pharma, Inc. (NASDAQ:REPH) major shareholder Healthcare Master Fun Broadfin sold 47,549 shares of the company’s stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $9.64, for a total transaction of $458,372.36. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Healthcare Master Fun Broadfin also recently made the following trade(s):
- On Thursday, November 30th, Healthcare Master Fun Broadfin sold 222,616 shares of Recro Pharma stock. The shares were sold at an average price of $9.58, for a total transaction of $2,132,661.28.
- On Tuesday, November 21st, Healthcare Master Fun Broadfin sold 102,440 shares of Recro Pharma stock. The shares were sold at an average price of $9.50, for a total transaction of $973,180.00.
- On Friday, November 24th, Healthcare Master Fun Broadfin sold 172,208 shares of Recro Pharma stock. The shares were sold at an average price of $9.45, for a total transaction of $1,627,365.60.
Shares of Recro Pharma, Inc. (REPH) opened at $9.91 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50. Recro Pharma, Inc. has a 1-year low of $5.81 and a 1-year high of $9.96.
A number of equities research analysts have recently commented on REPH shares. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $8.25 price objective on the stock in a research note on Wednesday, August 16th. Piper Jaffray Companies reissued a “buy” rating and set a $11.00 target price on shares of Recro Pharma in a research note on Friday, October 27th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $11.65.
Recro Pharma Company Profile
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
What are top analysts saying about Recro Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Recro Pharma Inc. and related companies.